Tevogen Bio Holdings Inc.
TVGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $27 | $291 | $105 | $104 |
| Gross Profit | -$27 | -$291 | -$105 | -$104 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,111 | $2,700 | $3,195 | $2,836 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,591 | $2,454 | $7,056 | $6,423 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,702 | $5,154 | $10,251 | $9,260 |
| Operating Income | -$5,729 | -$5,445 | -$10,356 | -$9,363 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | -$59 | -$11 | -$81 |
| Pre-Tax Income | -$5,727 | -$5,504 | -$10,367 | -$9,445 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,727 | -$5,504 | -$10,367 | -$9,250 |
| % Margin | – | – | – | – |
| EPS | -0.03 | -0.031 | -0.065 | -0.052 |
| % Growth | 2% | 53% | -25.2% | – |
| EPS Diluted | -0.03 | -0.031 | -0.065 | -0.052 |
| Weighted Avg Shares Out | 196,029 | 184,307 | 161,407 | 177,991 |
| Weighted Avg Shares Out Dil | 196,029 | 184,307 | 161,407 | 177,991 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $62 | $38 | $25 | $16 |
| Depreciation & Amortization | $27 | $291 | $105 | $104 |
| EBITDA | -$5,637 | -$5,175 | -$10,237 | -$9,325 |
| % Margin | – | – | – | – |